Research at the Paul-Ehrlich-Institut
Research at the Paul-Ehrlich-Institut (PEI) traditionally focuses on medicinal issues and life sciences questions that already encouraged Nobel Prize winner Paul Ehrlich to conduct his groundbreaking work at the turn of the 19th and 20th centuries. Already at that time, Paul Ehrlich dealt with both fundamental and applied research questions working e.g. on the theory of antibody formation and the determination of antisera efficacy, respectively. In 1899, the "Institute for Serum Research and Testing" moved from Berlin to Frankfurt am Main, where it was renamed the "Royal Institute for Experimental Therapy". Today’s PEI is the direct successor to the Frankfurt institute.
From its earliest days, the PEI addressed scientific questions in the field of biomedicines, for which it is the competent German testing agency to this day. Biomedicines include vaccines for human and veterinary use, immunobiological and biotechnological medicinal products, blood products, cell and gene therapy medicinal products, and tissue.
Our research programme gives a clear overview on the amalgamation of regulatory and research duties, defines an appropriate general framework for expedient research activities and presents a concise vision on the future research strategy to meet emerging PEI-specific challenges.
The further development of the research infrastructure, the support with respect to grant application or the management of cross-divisional research projects, the development and maintenance of training programmes for young researchers, the preparation for internal and external evaluations, and the written reply to research-dependent inquiries are coordinated by the Research Manager in cooperation with the internal Research Working Group and in consultation with the President of the PEI.
Based on the respective recommendations of the German Science Foundation (Deutsche Forschungsgemeinschaft), the PEI has implemented guidelines that define the basis for scientific working and acting at the Paul-Ehrlich-Institut ("Grundlagen für wissenschaftliches Arbeiten und Handeln am Paul-Ehrlich-Institut"). This includes the guideline for the safeguarding of good scientific practice and the handling of scientific misconduct.
The PEI has commissioned Prof. Dr. Hansjörg Schild (Institut für Immunologie, Universitätsmedizin, Johannes Gutenberg-Universität Mainz, Germany) and Prof. Dr. Johannes Löwer (former PEI president) as ombudspersons for the handling of all questions and problems regarding the principles of good scientific practice.